Analysis updated Oct 24, 2026 — scores and signals refreshed daily.
Prelude Therapeutics Incorporated (PRLD) stock research. Updated Oct 24, 2026. Q-Score 72/100 — Strong Buy. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Strong Buy (72.0) (grade A). 29 signals analyzed (24 differentiated alt-data).
StoQuant's analysis of Prelude Therapeutics Incorporated (PRLD) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
PRLD stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-27 | $4.05 | $3.86 | $3.89 |
| 2026-08-04 | $4.58 | $4.41 | $4.52 |
| 2026-08-13 | $5.91 | $5.21 | $5.36 |
| 2026-08-21 | $6.82 | $6.40 | $6.63 |
| 2026-08-31 | $5.63 | $5.24 | $5.60 |
| 2026-09-09 | $5.34 | $5.06 | $5.09 |
| 2026-09-17 | $4.91 | $4.49 | $4.57 |
| 2026-09-25 | $4.00 | $3.85 | $3.88 |
| 2026-10-05 | $3.81 | $3.55 | $3.77 |
| 2026-10-13 | $3.90 | $3.43 | $3.56 |
| 2026-10-21 | $3.78 | $3.47 | $3.65 |
How Prelude Therapeutics Incorporated stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CGEN | Compugen Ltd. | $256M | — |
| ACHV | Achieve Life Sciences, Inc. | $244M | 36.0 |
| PRE | Prenetics Global Limited | $261M | — |
| PMI | Picard Medical, Inc. | $240M | — |
| SENS | Senseonics Holdings, Inc. | $239M | — |
View all Health Care stocks by valuation and signals →
Prelude Therapeutics Incorporated (PRLD) scores Strong Buy (72.0), and the composite conceals a 54-point disagreement between its dimensions. It is strongest on competitive moat at 88 and valuation at 74, and weakest on technicals at 34. A stock can carry competitive moat that high while technicals sits at 34; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 88 |
| valuation | 74 |
| analyst consensus | 60 |
| technicals | 34 |
StoQuant analyzes 29 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Prelude Therapeutics Incorporated (PRLD): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/PRLD"><img src="https://stoquant.com/badge/PRLD.svg" alt="Prelude Therapeutics Incorporated (PRLD) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.